
Conference Coverage
20 days ago
ID Week Highlights Part 1Latest Content

Cefazolin Possibly Superior, Probably Safer than Cloxacillin for MSSA Bacteremia

CHMP Recommends Dolutegravir, Dolutegravir/Lamivudine for Children With HIV

Ebola Outbreak Reaches 11,145 Cases, 5437 Deaths

Reports Say US Loses Measles Elimination Status After 26 Years

Peggy Lillis Foundation Expands C diff Campaign to Pediatric Population, Survivors

Shorts










Videos
Contagion Digital Edition









Continuing Medical Education
All News

The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.

Here is some important information around this pathogen and the intestinal infection.

Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.

Enteric fever (typhoid or paratyphoid fever) infection in travelers returning to the US is likely resistant to ciprofloxacin, and with some cases also resistant to ceftriaxone, CDC investigators advise treatment guided by susceptibility.

The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.

Here is a case that was linked to a unique travel history and led to a series of acute health issues.

Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.

Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.

CDC reports 10,772 confirmed Ebola cases and 5234 deaths, making this the second-largest outbreak on record. Kenya and Nigeria have reported cases.

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

Recent urinary tract infection guideline updates from multiple international medical societies highlight evolving recommendations, including a major shift in classification, moving from anatomy- and risk factor–based definitions toward distinguishing localized from systemic infections.









































































































